Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
Recruiting · NCT06016634 · Interventional (participants receive a specific treatment) · Lead sponsor: University of California, Davis
View the official record on ClinicalTrials.gov →Interventions studied
Alendronate Sodium
What this trial is about
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
- Ability to provide written informed consent
- Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
- Negative urine pregnancy test for anyone of childbearing potential at study entry
Exclusion criteria
- Pregnant women
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Hospitalizations (for any cause) within 2 weeks of study entry
Where it is running
1 location listed across 1 US state.
- UC Davis Comprehensive Cancer Center - Sacramento, California, United States